What current guidance recommends
In type 2 diabetes, the American Diabetes Association recommends assessing the risk of liver scarring related to metabolic dysfunction-associated steatohepatitis (MASH), including when liver enzymes are normal. MASH is the form of metabolic dysfunction-associated steatotic liver disease (MASLD) that involves liver inflammation and injury. The usual starting point is FIB-4, a score calculated from age, two liver enzymes and a platelet count[6].
The ADA recommends further assessment when FIB-4 is elevated. The usual next test is transient elastography, a scan that measures liver stiffness. The enhanced liver fibrosis (ELF) blood test is an alternative when a scan is unavailable. Age and other risk factors can affect how clinicians interpret the score. A higher-risk result can lead to specialist evaluation, and a specialist may still consider a biopsy in selected cases [6] [7].
What screening studies found
In a prospective San Diego study of adults aged 50 or older with type 2 diabetes, 501 met eligibility criteria and 493 had enough imaging data for analysis. Among those 493, 322 (65%) met the study’s definition of fatty liver, 69 (14%) met criteria for advanced fibrosis and 29 (6%) met criteria for cirrhosis[5].
A London primary-care study included 287 of 300 participants. It identified MASLD in 186, significant fibrosis due to MASLD in 50, and advanced fibrosis due to MASLD in 31. Among people whose liver stiffness met the study’s threshold for significant fibrosis (8.1 kPa or higher), FIB-4 gave a false-negative result in 38% and ELF did so in 54% at the cutoffs used. These were comparisons with a liver stiffness threshold in one cohort. They do not represent universal miss rates or the performance of a multi-step screening program [3].
What the cost models estimated
The annual spending study in type 2 diabetes compared claims for people with and without a recorded fatty liver diagnosis. The models below estimate what could change under different screening pathways.
A 2026 economic model compared screening pathways in the United States and five European countries. Some noninvasive pathways were projected to save money and improve health relative to no screening. Others added costs, up to £18,572 per quality-adjusted life year gained. A quality-adjusted life year is a measure that combines length and quality of life. The biopsy pathways tested in the model cost more and yielded worse projected outcomes than no screening[1].
Treatment price and expected health gains shape the estimated value of semaglutide for MASH. In a separate 12-country model, screening followed by intensive lifestyle intervention was cost-effective under the model’s criteria in all 12 countries. Adding semaglutide to lifestyle intervention was cost-effective in 11 [2].
A 2016 U.S. model reached a different result using ultrasound, biopsy and an older treatment pathway. It projected fewer cases of cirrhosis and liver-related deaths, but also 0.02 fewer quality-adjusted life years because it assumed a reduction in quality of life during treatment. Removing that assumption changed the result to $42,134 per quality-adjusted life year gained[4]. The difference illustrates how assumptions about treatment after screening can change the result.